Compare · EPRX vs HEXO
EPRX vs HEXO
Side-by-side comparison of Eupraxia Pharmaceuticals Inc. (EPRX) and HEXO Corp. (HEXO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EPRX and HEXO operate in Pharmaceuticals and Biotechnology (Health Care), so they compete in similar markets.
- HEXO carries a market cap of $176.3M.
- EPRX has hit the wire 7 times in the past 4 weeks while HEXO has been quiet.
- HEXO has more recent analyst coverage (11 ratings vs 6 for EPRX).
- Company
- Eupraxia Pharmaceuticals Inc.
- HEXO Corp.
- Price
- $7.17-1.51%
- $0.70+3.98%
- Market cap
- -
- $176.3M
- 1M return
- +1.13%
- -
- 1Y return
- +83.61%
- -
- Industry
- Pharmaceuticals and Biotechnology
- Pharmaceuticals and Biotechnology
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 0
- Recent ratings
- 6
- 11
HEXO Corp.
HEXO Corp., through its subsidiaries, produces, markets, and sells cannabis in Canada. It offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. The company offers its adult-use and medical products under the HEXO brand name. Additionally, it offers cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brand; and cannabis products under Original Stash and Up brand names. The company was formerly known as The Hydropothecary Corporation and changes its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Kanata, Canada.
Latest EPRX
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Eupraxia Pharmaceuticals
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Latest HEXO
- Cash Flow Chronicles: Analyst Dissects Canadian Cannabis Balance Sheets, Market Trends Vs. The US
- EXCLUSIVE: Key Insights And 4 Predictions On Cannabis Sector Equity Research For 2024
- SEC Form 15-12G filed by HEXO Corp.
- 'North Carolina Senate Approves Medical Marijuana Regulatory Appointment As House Leader Says 'Heavy-Handed' Tactics Not Helping Legalization's Fate' - Marijuana Moment
- 'Major Marijuana Industry Players Launch Super Pac To Advance Cannabis Reform As 2024 Election Heats Up' - Marijuana Moment
- 'Schumer Touts Marijuana Banking Bill As Bipartisan Priority, And Republican Sponsor Is Optimistic As Long As Measure Isn't Expanded' -Marijuana Moment Report
- Tilray's HEXO Acquisition Creates Canada's Top Cannabis Company With 44% Market Share Boost
- SEC Form 25-NSE filed by HEXO Corp.
- SEC Form F-10POS filed by HEXO Corp.
- SEC Form F-10POS filed by HEXO Corp.